I would say Acadia are more reliant on Daybue because of the failed label expansion of Nuplazid combined with their higher SG&A expenses required for maintaining a salesforce to sell the treatments. It was good that their guidance increased slightly for Nuplazid but it is clear the growth has slowed down and without label extension they need to look to other drugs and their pipeline isn't exactly full. The PWS hyperphagia is the only late-stage asset they have.
I would say Acadia are more reliant on Daybue because of the...
-
- There are more pages in this discussion • 582 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.38 |
Change
-0.270(1.98%) |
Mkt cap ! $1.710B | |||
| Open | High | Low | Value | Volume |
| $13.68 | $13.68 | $13.11 | $4.283M | 320.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $13.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.40 | 3328 | 3 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |